Fusion Antibodies PLC Exercise of Options (2933S)
07 Luglio 2020 - 3:12PM
UK Regulatory
TIDMFAB
RNS Number : 2933S
Fusion Antibodies PLC
07 July 2020
Fusion Antibodies plc
("Fusion" or the "Company")
Exercise of Options
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces that has made an
application to the London Stock Exchange for the admission to
trading on AIM ("Admission") of 12,500 new ordinary shares of 4p
each in the Company ("New Ordinary Shares"). The New Ordinary
Shares are being issued pursuant to the exercise of options by an
employee of the Company. The options were granted pursuant to the
Company's Historic Option Scheme (as defined in the Company's
admission document dated 12 December 2017) and have an exercise
price of 4p per option. The New Ordinary Shares will rank pari
passu in all respects with the Company's existing ordinary shares
and Admission is expected to become effective on or around 13 July
2020.
Total Voting Rights
On Admission, the issued share capital of the Company will
consist of 25,437,025 Ordinary Shares, with one voting right per
share. The Company does not hold any Ordinary Shares in treasury.
Therefore, the total number of Ordinary Shares and voting rights in
the Company will be 25,437,025 . The above figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328
5656
James Reeve / Asha Chotai
Walbrook PR Tel: +44 (0)20 7933
8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741
001
Paul McManus Mob: +44 (0)7980 541
893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 100 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster, with the optimal drug candidate and ultimately speed
up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEMZGGNFNGGGZM
(END) Dow Jones Newswires
July 07, 2020 09:12 ET (13:12 GMT)
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Apr 2023 a Apr 2024